Wantai Canghai Biotechnology Co., Ltd. Wantai Canghai is a private technology company engaged in vaccine research and development. In 2012, it launched the world's first hepatitis E vaccine, and in 2019, it launched the world's fourth and first domestic cervical cancer vaccine-Xinkening® . Product introduction: Hepatitis E vaccine: Yikening® The world's first hepatitis E vaccine on the market Unique E. coli expression platform: efficient and safe Have a high degree of independent intellectual property rights: multiple international and domestic invention patents Papillomavirus vaccine: Xinkening® National Class A new drug, the first domestically approved HPV vaccine The third cervical cancer vaccine supplier in the world More cost-effective, the first domestically approved 2 injections for 9-14 years old Immunization program